Tags

Type your tag names separated by a space and hit enter

Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
J Pediatr. 2006 Nov; 149(5):603-610.JPed

Abstract

OBJECTIVE

The safety of a booster dose of a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine was evaluated in adolescents previously vaccinated with five doses of acellular pertussis-containing vaccine.

STUDY DESIGN

Adolescents (n = 319) previously vaccinated with either 5 doses of diphtheria-tetanus-acellular pertussis (DTaP) (n = 193) or 4 doses of DTaP plus another acellular pertussis-containing vaccine received one dose each of Tdap and hepatitis A vaccine in a double-blinded, randomized, crossover trial. Rates of adverse events (AEs) after vaccination with Tdap versus hepatitis A and rates of local AEs among adolescents vaccinated with Tdap (sixth acellular pertussis-containing vaccine dose) versus rates in these same individuals after vaccination with their fifth DTaP dose were assessed.

RESULTS

After Tdap, pain (63.6%), redness (51.7%), and swelling (41.4%) were the most frequently reported AEs. Large injection site swelling (swelling > 100 mm, arm circumference increase > 50 mm or diffuse swelling interfering with daily activities) occurred in three adolescents and resolved without sequelae. After the sixth dose of acellular pertussis-containing vaccine, adolescents reported more pain and less redness and swelling compared with incidences of these AEs reported when these same individuals received their fifth DTaP dose.

CONCLUSIONS

These results suggest that Tdap is well tolerated as a sixth consecutive dose of acellular pertussis-containing vaccine.

Authors+Show Affiliations

Children's Hospital, Johannes Gutenberg University, Mainz, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17095328

Citation

Zepp, Fred, et al. "Safety of Reduced-antigen-content Tetanus-diphtheria-acellular Pertussis Vaccine in Adolescents as a Sixth Consecutive Dose of Acellular Pertussis-containing Vaccine." The Journal of Pediatrics, vol. 149, no. 5, 2006, pp. 603-610.
Zepp F, Knuf M, Habermehl P, et al. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr. 2006;149(5):603-610.
Zepp, F., Knuf, M., Habermehl, P., Mannhardt-Laakmann, W., Howe, B., & Friedland, L. R. (2006). Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. The Journal of Pediatrics, 149(5), 603-610.
Zepp F, et al. Safety of Reduced-antigen-content Tetanus-diphtheria-acellular Pertussis Vaccine in Adolescents as a Sixth Consecutive Dose of Acellular Pertussis-containing Vaccine. J Pediatr. 2006;149(5):603-610. PubMed PMID: 17095328.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. AU - Zepp,Fred, AU - Knuf,Markus, AU - Habermehl,Pirmin, AU - Mannhardt-Laakmann,Wilma, AU - Howe,Barbara, AU - Friedland,Leonard R, PY - 2005/11/21/received PY - 2006/03/15/revised PY - 2006/06/09/accepted PY - 2006/11/11/pubmed PY - 2007/1/5/medline PY - 2006/11/11/entrez SP - 603 EP - 610 JF - The Journal of pediatrics JO - J Pediatr VL - 149 IS - 5 N2 - OBJECTIVE: The safety of a booster dose of a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine was evaluated in adolescents previously vaccinated with five doses of acellular pertussis-containing vaccine. STUDY DESIGN: Adolescents (n = 319) previously vaccinated with either 5 doses of diphtheria-tetanus-acellular pertussis (DTaP) (n = 193) or 4 doses of DTaP plus another acellular pertussis-containing vaccine received one dose each of Tdap and hepatitis A vaccine in a double-blinded, randomized, crossover trial. Rates of adverse events (AEs) after vaccination with Tdap versus hepatitis A and rates of local AEs among adolescents vaccinated with Tdap (sixth acellular pertussis-containing vaccine dose) versus rates in these same individuals after vaccination with their fifth DTaP dose were assessed. RESULTS: After Tdap, pain (63.6%), redness (51.7%), and swelling (41.4%) were the most frequently reported AEs. Large injection site swelling (swelling > 100 mm, arm circumference increase > 50 mm or diffuse swelling interfering with daily activities) occurred in three adolescents and resolved without sequelae. After the sixth dose of acellular pertussis-containing vaccine, adolescents reported more pain and less redness and swelling compared with incidences of these AEs reported when these same individuals received their fifth DTaP dose. CONCLUSIONS: These results suggest that Tdap is well tolerated as a sixth consecutive dose of acellular pertussis-containing vaccine. SN - 0022-3476 UR - https://www.unboundmedicine.com/medline/citation/17095328/Safety_of_reduced_antigen_content_tetanus_diphtheria_acellular_pertussis_vaccine_in_adolescents_as_a_sixth_consecutive_dose_of_acellular_pertussis_containing_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-3476(06)00553-1 DB - PRIME DP - Unbound Medicine ER -